Drug firm Lupin on Friday said it has received approval from the US health regulator to market a generic medication to treat seizures.

The company has received approval from the US Food and Drug Administration (USFDA) to market Topiramate extended-release capsules in the US, the drug firm said in a statement.

The product is a generic equivalent of Supernus Pharmaceuticals, Inc.'s Trokendi XR extended-release capsules, it added.